Literature DB >> 7477126

P-glycoprotein--a marker of cancer-cell behavior.

H M Pinedo, G Giaccone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7477126     DOI： 10.1056/NEJM199511233332111

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Authors:  U Mayer; E Wagenaar; J H Beijnen; J W Smit; D K Meijer; J van Asperen; P Borst; A H Schinkel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.

Authors:  G Weinländer; G Kornek; M Raderer; M Hejna; C Tetzner; W Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 3.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Development of multidrug-resistance convertors: sense or nonsense?

Authors:  L van Zuylen; K Nooter; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

5.  Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice.

Authors:  Bao-Jin Zhai; Ze-Yong Shao; Chun-Liang Zhao; Kai Hu; Feng Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

6.  Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma.

Authors:  S Krishnakumar; K Mallikarjuna; N Desai; A Muthialu; N Venkatesan; A Sundaram; V Khetan; M P Shanmugam
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

7.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.

Authors:  G M Kolfschoten; T M Hulscher; H M Pinedo; E Boven
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

9.  The Effect of P-Glycoprotein (P-gp), Nuclear Factor-Kappa B (Nf-κb), and Aldehyde Dehydrogenase-1 (ALDH-1) Expression on Metastases, Recurrence and Survival in Advanced Breast Cancer Patients

Authors:  Yan Wisnu Prajoko; Teguh Aryandono
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.